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Abstract
The objective of this review is to present the impact of uncontrolled use of anti-
microbial agents in chicken husbandry on emergence of drug-resistant Campylo-
bacter in humans. The absence of an Antimicrobial Resistance Monitoring System 
(ARMS) in most developing countries of the world, amidst trade’s globalization of 
animals and animal products, helped in the recent decade in spreading of drug-
resistant organisms across the world’s food chains.
The emergence of drug resistance in Campylobacter organisms was associated with 
their transmission from animals and their products to humans. This transmission 
of drug-resistant Campylobacter resulted in serious failure of treatment regimens 
prescribed to infected humans.
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Introduction
Most developing countries around the world lack a system 
that monitors the drug-resistance pattern in bacteria that 
cause serious zoonoses around the globe [1]. The Antimi-
crobial Resistance Monitoring System (ARMS) should be es-
tablished in each country, including in its structure selected 
personnel from The Ministry of Health, Veterinary Medicine 
Syndicate, Department of Agriculture, and representatives 
from the WHO (World Health Organization), FAO (Food and 
Agriculture Organization), and OIE (Office International des 
Epizooties).
The ARMS main role is to receive zoonoses-causing bacteria 
isolates from specialized centers in the developing countries 
for speciation and/or serotyping, and for determining their 
antimicrobial susceptibility to a wide spectrum of drugs avail-
able in the world’s market.
An annual report should be prepared by each country, pre-
senting the frequency of resistance to different drugs by 
the tested zoonotic bacteria, such as Campylobacter organ-
isms, with the inclusion of information related to the iso-
late source, and the region. Such annual report should be 
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available through publications that are distributed to librar-
ies around the world, and preferably through an established 
web site net work to cover most developing countries, or at 
least a network with a regional coverage. The annual reports 
should be accessible by large communities of the world, in-
cluding personnel in the fields of human medicine, veterinary 
medicine, animal production, food industry, consumers, and 
touristic industries.
Such availability of data will help physicians, veterinarians, 
managers in animal production and food processing, con-
sumers, and tourists to be aware of the sources of the zoo-
notic bacteria and the in-vitro efficacy of the tested drugs. In 
addition, the presentation of such annual reports will build a 
pressure on animal and food industry to improve their hus-
bandry and hygiene measures, to reach to a safer food that 
improves the livelihood of the consumers around the globe.
The reader of this review will be exposed to conclude re-
searches from different parts of the world, related to the 
problem of drug-resistance in Campylobacter organisms that 
originated from poultry. This exposure will raise the aware-
ness to the seriousness of the abuse of drugs in animal pro-
duction management, affecting the human health by organ-
isms that are resisting the drugs of choice. 
Campylobacter infection in humans
Campylobacter organisms are etiologic agents of diarrhea 
in humans, and are composed of two predominant species 
namely, Campylobacter jejuni and Campylobacter coli [10; 
11]. Campylobacter infection is rated as the most common 
cause of bacterial gastro-enteritis in the developed countries 
[12]. 
The infection seems self-limiting in two thirds of patients, 
after an incubation period of three days, leading to symp-
toms of abdominal pain and diarrhea; however, the other 
one third of cases suffer of fever, general aches, dizziness, 
and delirium during around 24 hours before the onset of 
the known gastrointestinal symptoms. The one third portion 
of patients manifest a severe pathogenesis by the Campylo-
bacter, requiring immediate therapeutic intervention, usually 
by known drugs of choice, namely fluoroquinolone or mac-
rolide antimicrobials [22].
The early clinical trials with fluoroquinolone showed an ap-
parent efficacy against Campylobacter infection that led to 
a recommendation to use this drug as prophylaxis during 
travels of Europeans to outside their continent [23; 24;.25; 
26; 27].
Veterinary abuses of quinolones in poultry 
The two predominant species of Campylobacter in human 
infections (C. jejuni and C. coli), have their main reservoir 
in poultry [11], allowing their inclusion with other members 
defined under ‘food pathogens’. The Fluroquinolone ‘enro-
floxacin’ was introduced into poultry in the year 1987, just 
one year before the ciprofloxacin was introduced as a drug 
for humans [28]. The use of enrofloxacin in poultry spread to 
almost every country, due to its high efficacy in treatment of 
the most predominant secondary infections in poultry, caused 
by E. coli [28], especially the colibacillosis that follows a com-
mon primary infection by Mycoplasma gallisepticum [29]. The 
use of enrofloxacin in the first five years of its introduction 
to poultry resulted in 29% of Campylobacter isolates build-
ing resistance to nalidixic acid, flumequine, enrofloxacin and 
ciprofloxacin [28]. It is worth noting that in the year 1982 
no fluoroquinolone-resistant Campylobacter strains were iso-
lated from human cases in Netherland; however, resistance 
to this drug started to increase drastically in human isolates 
after 3-4 years of enrofloxacin introduction to poultry [30].
A controlled experiment by Jacobs-Reitsma et al. in 1994 
showed a direct effect of the application of fluoroquinolone 
on emergence of resistance in Campylobacter recovered of 
chickens. This led the authors to recommend a reassessment 
of the use of fluoroquinolones in animal husbandry. 
The United Kingdom delayed the introduction of fluoroqui-
nolone in its poultry until 1994, while the use of enrofloxacin 
in poultry of mainland Europe started earlier in 1987. This 
helped in comparison of the frequency of Campylobacter re-
sistance to enrofloxacin in UK chicken versus chicken of the 
other mainland European countries. The frequency of the 
enrofloxacin resistance in Campylobacter isolates of the UK-
chickens was seven times less than that of the other mainland 
European-chickens [31], confirming the hypothesis of emer-
gence of drug-resistance in poultry isolates of Campylobacter 
due to introduction of enrofloxacin medication on poultry 
farms. 
It is worth noting that many other studies have attributed the 
emergence of drug-resistance in Campylobacter to the use of 
antimicrobial agents in poultry production [32]. These alarm-
ing documented research led to banning of the use of fluo-
roquinolone in poultry husbandry, effective the year 2005.
The research documented in Belgium, Austria, Minnesota 
(USA), Brazil, and Turkey pointed at the emergence of drug-
resistance in Campylobacter isolates after the introduction 
of fluoroquinolones as a medication inpoultry. In Belgium, 
alarming high rates of drug-resistance in Campylobacter re-
covered from chickens (44.2%), suggested that the use offlu-
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oroquinolones in poultry is most likely behind the increasing 
drug-resistance in human isolates [5]. The rate of isolations 
of Campylobacter organisms from chicken broilers at Styrian 
slaughter house in Austria was 54%, and the frequency of 
resistance to ciprofloxacin was 62.2%, suggesting that such 
a high frequency of drug-resistance was due to the fact that 
enrofloxacin was the most commonly used drug in broiler 
production in Austria [6]. In Minnesota, a central north state 
of the USA, reported a rapid rise in quinolone resistance of 
human Campylobacter jejuni that coincided with the licensing 
of fluoroquinolones in poultry; moreover, an epidemiology 
was concluded, based on comparing subtypes of drug-resis-
tant chicken versus human isolates of C. jejuni, proving that 
‘the use of fluoroquinolones in their poultry had a primary 
role in increasing resistance to quinolones among the tested 
C. jejuni isolates recovered from humans [7].
The conclusion reached in Brazil, following a documentation 
of high frequency of resistance to fluoroquinolones in C. je-
juni isolates recovered from children, especially in the absence 
of previous history of children’s treatment with this drug, 
suggested an animal origin of the drug-resistant C. jejuni due 
to veterinary use of enrofloxacin for treating poultry bacterial 
diseases [9].
Last but not least, the documented research from Turkey, 
including data between 1992-2000, proved that the first 
fluoroquinolone-resistant Campylobacter isolate recovered 
from broiler chickens was in the year 1992, occurring after 
two years of enrofloxacin inclusion in treatment programs 
of Turkish poultry farms. A significant rise in resistance of 
Campylobacter occurred in the year 2000, in which 75.5% 
of the isolates were resistant to enrofloxacin and 73.0% to 
ciprofloxacin. The authors concluded that ‘The uncontrolled 
use of fluoroquinolones in animals in Turkey is behind this 
rise in resistance [8]. 
It is worth noting that the fluoroquinolone member used in 
farm animals was enrofloxacin (Brand name: Baytril), while 
that used for humans was ciprofloxacin (Brand name: Cipro). 
The previous mentioned researches from different countries 
proved that the use of Baytril, as prophylactic for chickens is 
implicated in increasing resistance to Cipro. In addition, the 
bacteria that develop resistance to the Macrolide, used in 
chicken under the name Tylosin, are often cross-resistant to 
erythromycin that is used against Campylobacter infection 
in humans, and for treatment of people that are allergic to 
penicillin. 
Unfortunately, the fluoroquinolone is still used on a wide 
scale in poultry husbandry of many Middle Eastern countries, 
in the absence of periodic reports to monitor the buildup of 
drug resistance in the poultry and human isolates of Cam-
pylobacter. 
Mechanism of Quinolone and Macrolide 
Resistance
The long term use of quinolone and macrolide in poultry 
husbandry led to mutations in the Campylobacter organisms 
present in aviant intestine, which was transmitted on a wide 
scale into the poultry industry.
The fluoroquinolones, such as enrofloxacin, target the DNA 
gyrase enzyme in the bacteria. A mutation in the gyrA-en-
coding subunit of the DNA gyrase results in one or more 
amino acid substitutions [35]. These substitutions exist within 
the DNA-binding domain. A change in the sequence of ami-
no acids in such a domain may lead to a resistance in the 
Campylobacter organism to fluoroquinolones. This important 
domain is referred to in literature as the QRDR (quinolone-
resistance determining region). Some substitutions of amino 
acids in the QRDR domain have been characterized and corre-
lated to quinolone-resistance; examples of such substitutions 
are the Thr-86-Ile substitution [34; 35] and the Asn-203-Ser 
substitution [34].
The mechanism of Macrolide resistance in Campylobacter 
organisms is also studied, resulting in different conclusions. 
The Erythromycin, a commonly used macrolide in poultry, in-
hibits the protein synthesis in Campylobacter organisms. This 
inhibition occurs due to the binding of the drug to ribosomes 
of this bacterium. The binding leads to dissolution of the 
tRNA-amino acid chain complex, thus preventing the bacte-
rial growth by binary fission. The build-up of resistance in 
Campylobacter organisms treated with macrolides seems to 
be accomplished by two mechanisms: the first mechanism is 
by modification of the macrolide binding-target by a genetic 
mutation, and the second mechanism is by exclusion of the 
drug from the Campylobacter cell by an efflux process [26]. 
The most common mechanism for emergence of resistance to 
macrolide is the first, in which point mutations occur at posi-
tion 2074 and/or 2075 in the 23SrRNA of the 50S-ribosomal 
subunit or by the mutations in L4 and L22 ribosomal proteins 
[26; 36].
The second less frequent mechanism for building resistance in 
Campylobacter organisms to a wider range of antimicrobials 
is by the Cme-ABC efflux pump. This mechanism results in 
expulsion or exclusion of the Macrolides and other antimi-
crobials such as quinolones, from the Campylobacter cells. 
This expulsion pump can promote both intrinsic and acquired 
resistance to a range of antimicrobial agents [37; 38]. 
iMedPub Journals
Our Site: http://www.imedpub.com/
4 © Under License of Creative Commons Attribution 3.0 License
2012
Vol. 2 No. 4:1
doi: 10.3823/719
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
The understanding of the above mechanisms, that result 
in emergence of resistance in Campylobacter organisms to 
drugs of choice (quinolones and macrolides), incriminates the 
point mutations as the most common mechanisms foracquir-
ing drug resistance by these organisms.
These point mutations become stable in the Campylobacter 
populations harboring the poultry host, transferring such re-
sistance trait to their daughter cells, regardless of the measure 
taken by poultry industry to ban the practice of application of 
quinolones. Actually, the resistance to quniolones and macro-
lides in Campylobacter isolates of poultry persisted until after 
the year 2005, the year of banning the use of quinolones in 
poultry husbandry [13; 14; 15].
Drug-resistance post the banning of Quinolone
The drug resistance in Campylobacter isolates, post the ban-
ning of quinolone application in poultry husbandry in the 
year 2005, is persisting. 
In the year 2006, just one year following the banning of 
quinolones applications in poultry, sporadic reports docu-
mented different levels of quinolone and macrolides resis-
tance in poultry isolates recovered from different parts of 
the world [16; 17; 18; 19]. Two years following the banning 
of quinolone use in poultry, reports started to commend the 
success of this banning approach in reducing the resistance 
to quinolones in avian isolates [20]; following such a success, 
more efforts were directed towards the macrolide abuse in 
poultry, especially the emergence of Campylobacter isolates 
with resistance to erythromycin [21].
The sporadic reports in the four years, between 2008 and 
2011, related to frequency of resistant avian Campylobacter 
isolates to quinolones and macrolides included major works 
by the Canadian Integrated Program for Antimicrobial Resis-
tance Surveillance (CIPARS, 2011). CIPARS identified greater 
than 10% emerging prevalence of ciprofloxacin-resistant 
Campylobacter isolates recovered from chicken marketed in 
British Colombia and Saskatchewan provinces. This preva-
lence had an increasing trend between 2007 and 2010.
In April of 2011, EFSA and the European Center for Disease 
Prevention and Control (ECDC) reported latest results of an-
timicrobial resistance, as submitted by EU countries (ECDC, 
2011). Unfortunately, there was a high resistance to cipro-
floxacin, ranging from 33% to 78% in chickens, chicken 
meat, pigs and cattle. EFSA’s report indicated that resistance 
in these zoonotic bacteria persisted after 2005, which was 
most likely due to continuing practice of using these drugs 
by the European farmers. 
The National Antimicrobial Resistance Monitoring System of 
the United States Department of Agriculture (NARMS, 2009) 
reported between 1998-2009 the resistance in chicken 
Campylobacter isolates to 10 antimicrobials that fall under 
6 antimicrobial classes namely the Aminoglycosides (Gen-
tamicin), Lincosamides (Clindamycin), Macrolides/Ketolides 
(Azithromycin, Erythromycin, Telithromycin), Phenicols (Chlor-
amphenicol, Florflenicol), Quinolones (Ciprofloxacin, Nalidixic 
acid), and Tetracyclines (Tetracycline). The highest consistent 
resistance in Campylobacter, in the last 4 years of the report’s 
data was to tetracycline ranging between 49.6-56.6%, fol-
lowed by Nalidixic acid (8.8-33.3%), Cipofloxacin (8.8-32.1%), 
Erythromycin and Gentamicin (0.0-1.3%), and Azithromycin 
(0-1%). The Campylobacter recovered from chickens had no 
resistance in the last 4 years of the report to clindamicin, 
telithromycin, and florfenicol. 
In conclusion, the abuse of drugs in poultry that results in 
resistance of human Campylobacter organisms to drugs of 
choice is a neglected issue in many developing countries, 
resulting in a significant negative impact on the livelihood of 
their people and on tourists that visit such countries. It is rec-
ommended to establish a Regional Antimicrobial Resistance 
Monitoring System (RARMS) in the Middle East, composed 
of selected personnel from the Ministries of Health, Veteri-
nary Medicine syndicates, and Departments of Agriculture, 
and representations from WHO (World Health Organization), 
FAO (Food and Agriculture Organization) and OIE (Office In-
ternationale des Epizooties). The RARMS main role will be to 
receive Campylobacter isolates from specific stations in all 
Middle Eastern countries for speciation and/or typing and for 
determining their susceptibility to a wide spectrum of anti-
microbials. An annual report should be published to include 
the frequency of resistance to different drugs by Campylo-
bacter organisms, the isolates source, region, and the country 
of the Middle East. This report could be downloaded on a 
special web site of the RARMS, for an easy access by the hu-
man medical communities, veterinarians, food industry, local 
people of the Middle East, and tourists.
The alarming data of this review, related to the emergence 
of resistance to drugs of choice by poultry isolates of Campy-
lobacter, require an immediate decision to establish RARMS 
for the benefit of human and animal livelihood of the Middle 
East. 
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